Drugmaker Moderna announced that it has made progress in developing a preventive vaccine using mRNA technology for a certain form of melanoma and using it in conjunction with immunotherapy developed by fellow drugmaker Merck. The two companies are working together, and the vaccine/immunotherapy combination showed statistically significant positive results in a small study of patients who had the cancer surgically removed. The next step will be conducting Phase 3 clinical trials that are expected to begin next year.